Published in Eur J Immunol on September 01, 2002
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol (2004) 1.20
Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut (2003) 1.10
Polymorphisms in signal transducer and activator of transcription 3 and lung function in asthma. Respir Res (2005) 0.97
Cytokines and growth factors promote airway smooth muscle cell proliferation. ISRN Inflamm (2012) 0.81
Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015) 0.77
Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther (2016) 0.75
IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med (2007) 2.00
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin (2013) 1.92
Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest (2007) 1.84
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. Clin Ther (2005) 1.45
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood (2011) 1.43
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood (2006) 1.38
Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol (2009) 1.35
CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol (2007) 1.35
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol (2006) 1.26
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol (2011) 1.13
Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Ann Allergy Asthma Immunol (2010) 1.13
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood (2007) 1.12
In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood (2003) 1.12
The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol (2010) 1.11
Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol (2007) 1.11
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clin Biochem (2011) 1.08
Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol (2010) 1.06
Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst (2011) 1.05
Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Ann Allergy Asthma Immunol (2010) 1.04
Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One (2011) 1.02
Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol (2007) 0.98
Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir Med (2007) 0.97
Fibroblasts from human spleen regulate NK cell differentiation from blood CD34(+) progenitors via cell surface IL-15. J Immunol (2002) 0.97
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol (2010) 0.94
Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol (2009) 0.93
CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol (2004) 0.92
Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol (2006) 0.92
Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol (2004) 0.90
Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One (2008) 0.90
TLR ligands stimulation protects MSC from NK killing. Stem Cells (2014) 0.90
Immunotherapeutic applications of IL-15. Immunotherapy (2012) 0.90
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res (2009) 0.90
Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol (2010) 0.89
Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Rev Vaccines (2013) 0.89
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol (2005) 0.88
Asthma management failure: a flaw in physicians' behavior or in patients' knowledge? J Asthma (2011) 0.88
Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res (2007) 0.87
Human renal cancer stem cells. Cancer Lett (2012) 0.87
New insights into airway remodelling in asthma and its possible modulation. Curr Opin Allergy Clin Immunol (2008) 0.87
Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990-1999). Respir Med (2005) 0.86
Disability in COPD and its relationship to clinical and patient-reported outcomes. Curr Med Res Opin (2011) 0.86
Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol (2006) 0.86
Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir Med (2012) 0.86
Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One (2012) 0.85
Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organ J (2010) 0.85
Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. Respir Med (2009) 0.84
A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother (2011) 0.84
Harmful effect of immunotherapy in children with combined snail and mite allergy. J Allergy Clin Immunol (2002) 0.84
Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol (2005) 0.84
The clinical characteristics of respiratory allergy in immigrants in northern Italy. Int Arch Allergy Immunol (2008) 0.84
Clinical and cytologic characteristics of allergic rhinitis in elderly patients. Ann Allergy Asthma Immunol (2012) 0.84
Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev (2012) 0.83
The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Ann Allergy Asthma Immunol (2011) 0.83
Patients with asthma and comorbid allergic rhinitis: is optimal quality of life achievable in real life? PLoS One (2012) 0.83
Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol (2005) 0.83
Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol (2003) 0.83
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy (2013) 0.83
When allergic rhinitis is not only allergic. Am J Rhinol Allergy (2009) 0.82
Allergy training and immunotherapy in Latin America: results of a regional overview. Ann Allergy Asthma Immunol (2013) 0.82
Serum cytotoxic T lymphocyte-associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. J Allergy Clin Immunol (2008) 0.82
Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics Clin Appl (2014) 0.82
Chronic obstructive pulmonary disease patient well-being and its relationship with clinical and patient-reported outcomes: a real-life observational study. Respiration (2011) 0.82
The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study. Ann Allergy Asthma Immunol (2008) 0.82
Airway remodelling in children: when does it start? Curr Opin Allergy Clin Immunol (2007) 0.81
The safety of allergen specific sublingual immunotherapy. Curr Drug Saf (2007) 0.81
Impact of bariatric surgery on pulmonary function and nitric oxide in asthmatic and non-asthmatic obese patients. J Asthma (2011) 0.81
Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Curr Opin Allergy Clin Immunol (2013) 0.81
Molecular allergy diagnosis: we need to become more knowledgeable. Ann Allergy Asthma Immunol (2012) 0.81
Interferon-alpha triggers B cell effector 1 (Be1) commitment. PLoS One (2011) 0.81
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood (2002) 0.81
Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One (2011) 0.81
Cross-sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. Pediatr Allergy Immunol (2014) 0.80
Emerging drugs for allergic conjunctivitis. Expert Opin Emerg Drugs (2014) 0.80
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. Int Arch Allergy Immunol (2003) 0.80
Eosinophilic esophagitis: which role for food and inhalant allergens? Asia Pac Allergy (2012) 0.80
Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respir Res (2013) 0.80
Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol (2003) 0.80
Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol (2003) 0.80
Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol (2008) 0.80
Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol (2013) 0.80
Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol (2006) 0.79
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunol Lett (2012) 0.79
Emerging sublingual immunotherapy drugs. Expert Opin Pharmacother (2010) 0.79
Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets (2006) 0.79
Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene (2003) 0.79